An open label prospective pilot-study to determine the improvement of impaired endothelial function and endothelial progenitor cell numbers following treatment with Aliskiren 300 mg in patients with coronary artery disease and hypertension.
Phase of Trial: Phase IV
Latest Information Update: 14 Apr 2012
At a glance
- Drugs Aliskiren (Primary)
- Indications Hypertension
- Focus Pharmacodynamics
- Acronyms AGILITY
- 10 Jun 2017 Biomarkers information updated
- 14 Apr 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
- 16 Jun 2011 New trial record